ClinicalTrials.gg
DrugBiological

Bempegaldesleukin clinical trials

Also written NKTR-214 and BMS-986321.

studies test it
18
open now
1
in phase 3
4
first study started
2015

How each study uses bempegaldesleukin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the bempegaldesleukin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Bempegaldesleukin
9
BEMPEG
3

Development codes

NKTR-214
12
BMS-986321
6

Studies by the year they started

18 studies that test it; most in 2019 (6)

Studies that test bempegaldesleukin, by start year
YearStudies
20151
20161
20172
20181
20196
20203
20212
20221
20251

By phase

A phase 1/2 study counts in both.

Phase 1
10
Phase 2
10
Phase 3
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 14 · Other 4

Nektar Therapeutics (9) · Bristol-Myers Squibb (3) · Memorial Sloan Kettering Cancer Center (1) · Parker Institute for Cancer Immunotherapy (1) · The First Affiliated Hospital with Nanjing Medical University (1) · University of Wisconsin, Madison (1) · Pfizer (1) · Calithera Biosciences, Inc (1)

Often tested with

Tested in the same studies.

Nivolumab (1) · CDX-301 (1) · flt3 ligand protein (1) · Poly ICLC (1) · DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 Formulation INO-5151 (1) · Anlotinib (1) · Avelumab (1) · TAK-659 (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test bempegaldesleukin.

Studies

Open first, then newest update. How each study uses bempegaldesleukin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 18

Given beside what is tested · 3 — bempegaldesleukin is usual care or a partner of the new treatment

Codes

What other systems call bempegaldesleukin · ClinicalTrials.gg INT000548

  • MeSH (NLM) C000611752bempegaldesleukinOne source NLM
  • UNII (FDA) BNO1JG5MZCBEMPEGALDESLEUKINConfirmed FDA, NLM, Wikidata
  • Wikidata Q68010523bempegaldesleukinConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C131019BempegaldesleukinOne source FDA
  • DrugBank DB15140One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.